Literature DB >> 16483786

Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease.

Attila D Kovács1, Jill M Weimer, David A Pearce.   

Abstract

Batten disease, a lysosomal storage disorder, is caused by mutations in the CLN3 gene. The Cln3-knockout (Cln3-/-) mouse model of the disease exhibits many characteristic pathological features of the human disorder. Here, we show that Cln3-/- mice, similarly to Batten disease patients, have a deficit in cerebellar motor coordination. To explore the possible cellular cause of this functional impairment, we compared the vulnerability of wild type (WT) and Cln3-/- cerebellar granule cell cultures to different toxic insults. We have found that cultured Cln3-/- cerebellar granule cells are selectively more vulnerable to AMPA-type glutamate receptor-mediated toxicity than their WT counterparts. This selective sensitivity was also observed in organotypic cerebellar slice cultures. Our results suggest that lack of the CLN3 protein has a significant influence on the function of AMPA receptors in cerebellar granule neurons, and that AMPA receptor dysregulation may be a major contributor to the cerebellar dysfunction in Batten disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483786     DOI: 10.1016/j.nbd.2005.12.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   7.046


  34 in total

1.  Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Serena Ramji; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

2.  Abnormally increased surface expression of AMPA receptors in the cerebellum, cortex and striatum of Cln3(-/-) mice.

Authors:  Attila D Kovács; Caitlin Hof; David A Pearce
Journal:  Neurosci Lett       Date:  2015-09-12       Impact factor: 3.046

3.  Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Gábor Szénási; Péter Kiricsi; Eva Szabó; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2010-10-29       Impact factor: 5.250

4.  Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine.

Authors:  Rozzy Finn; Attila D Kovács; David A Pearce
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

5.  Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease).

Authors:  Graham W Kay; Marcel M Verbeek; Julie M Furlong; Michèl A A P Willemsen; David N Palmer
Journal:  Neurochem Int       Date:  2009-08-05       Impact factor: 3.921

6.  Modulation of Kv4.2/KChIP3 interaction by the ceroid lipofuscinosis neuronal 3 protein CLN3.

Authors:  Carolin Seifert; Stephan Storch; Robert Bähring
Journal:  J Biol Chem       Date:  2020-07-07       Impact factor: 5.157

Review 7.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

8.  Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Jill M Weimer; Jared W Benedict; Amanda L Getty; Charlie C Pontikis; Ming J Lim; Jonathan D Cooper; David A Pearce
Journal:  Brain Res       Date:  2009-02-20       Impact factor: 3.252

9.  Primary culture of neural cells isolated from the cerebellum of newborn and adult mucopolysaccharidosis type IIIA mice.

Authors:  L M Sutherland; K M Hemsley; J J Hopwood
Journal:  Cell Mol Neurobiol       Date:  2008-02-23       Impact factor: 5.046

Review 10.  Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.

Authors:  Sara Bozorg; Denia Ramirez-Montealegre; Mina Chung; David A Pearce
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.